Genital Herpes

29 registered clinical trials studyying Genital Herpes — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Sim NCT07330440	Changchun BCHT Biotechnology Co.	Phase 1
Completed	A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to NCT06033261	ModernaTX, Inc.	Phase 1 / Phase 2
Unknown	A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 NCT03595995	United BioPharma	Phase 2
Unknown	Knowledge of Young Adults About Genital Herpes NCT05675228	Université de Reims Champagne-Ardenne	—
Completed	A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease NCT05500053	Rational Vaccines Inc	—
Terminated	Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV NCT04222985	Sanofi Pasteur, a Sanofi Company	Phase 1
Terminated	Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection NCT03146403	Genocea Biosciences, Inc.	Phase 2
Completed	The VIBLOK SAfety and perFormancE Trial NCT03080961	CLJI Worldwide	N/A
Completed	Melatonin Effects on Genital Herpes in Brazilian Women NCT03831165	University of Sao Paulo General Hospital	Phase 4
Terminated	A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes NCT01765114	Devirex AG	Phase 2
Terminated	Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes NCT01658826	AiCuris Anti-infective Cures AG	Phase 2
Completed	Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent G NCT01281007	EMS	Phase 3
Completed	Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2 NCT01112956	Centers for Disease Control and Prevention	—
Completed	GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women NCT00808405	University of Washington	N/A
Completed	Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Pe NCT01346475	University of Washington	Phase 4
Completed	A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation NCT00723229	University of Washington	Phase 4
Terminated	Effect of HSV-2 Suppressive Therapy on Sexual Behavior NCT00495716	University of Washington	Phase 4
Completed	Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV NCT00527618	University of Washington	Phase 4
Completed	Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients NCT00477334	Novartis	Phase 4
Completed	HSV-2 Shedding Resolution After Acyclovir Treatment NCT00495573	University of Washington	—
Completed	Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis) NCT01390805	GlaxoSmithKline	—
Completed	Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions NCT01132716	Roxane Laboratories	N/A
Completed	Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions NCT01132729	Roxane Laboratories	N/A
Completed	Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Perso NCT00362297	University of Washington	Phase 4
Completed	Trial Evaluating Safety, Tolerability and Immune Response of AG-707 NCT00231049	Agenus Inc.	Phase 1
Completed	Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults Wit NCT00306787	Novartis Pharmaceuticals	Phase 3
Completed	Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection NCT00262106	Endo Pharmaceuticals	Phase 3
Completed	A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding NCT00129818	Novartis	Phase 4
Unknown	Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and t NCT00124878	Wawer, Maria J., M.D.	Phase 3